Draft Guidance for Industry on Gene Therapy Clinical Trials -- Observing Participants for Delayed Adverse Events; Availability
United States. Food and Drug Administration [FDA]
Federal Register 2005 August 23; 70(162): 49296-29297
Showing items related by title, author, creator and subject.
Guidance for Industry: Gene Therapy Clinical Trials -- Observing Participants for Delayed Adverse Events: Draft Guidance Center for Biologics Evaluation and Research [CBER] (United States) (2005-08)
Draft Guidance for Industry on Using a Centralized Institutional Review Boards Process in Multicenter Clinical Trials; Availability Unknown author (United States. Food and Drug Administration, 2005-03-28)